Go Pro
NASDAQ:CAPS

Capstone Therapeutics Q2 2026 Earnings Report

Capstone Therapeutics logo
$0.23 -0.01 (-5.88%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$0.23 +0.00 (+0.26%)
As of 07/24/2026 07:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Capstone Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
$0.12
Beat/Miss
N/A
One Year Ago EPS
N/A

Capstone Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$20.39 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Capstone Therapeutics Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Friday, August 14, 2026
Conference Call Time
9:30AM ET

Conference Call Resources

Capstone Therapeutics Earnings Headlines

AI billionaires are selling. Quickly.
Nvidia CEO Jensen Huang has logged 42 consecutive sell transactions - not a single buy. Peter Thiel liquidated his entire Nvidia position. SoftBank dumped $5.8 billion. And Michael Burry, who famously predicted the housing crash, is now betting against AI stocks. But 40-year investment veteran Alexander Green says the insiders are only half right - and that the biggest AI profits may still be ahead, potentially 10X larger, just not from where most investors are looking.tc pixel
Capstone Holding Stock Price History
See More Capstone Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Capstone Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Capstone Therapeutics and other key companies, straight to your email.

About Capstone Therapeutics

Capstone Therapeutics (NASDAQ:CAPS), a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

View Capstone Therapeutics Profile